Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.

HRX-0233 是一种小分子 MAP2K4 抑制剂，在 KRAS^G12C 突变型非小细胞肺癌模型中可在无明显毒性的情况下诱导显著的肿瘤回缩，并在 sotorasib 单药治疗过程中阻断受体酪氨酸激酶的反馈激活。HRX-0233 能实现 MAPK 通路的持续抑制，支持其在肺癌、结直肠癌及 AR 阴性前列腺癌研究中的应用。

MRTX849 analog 24 is an alkyne-containing click probe analogue of the MRTX849 inhibitor for KRAS G12C. It is specifically designed for studying the functionality of MRTX849.

GAGGVGKSAL 是免疫原性的野生型KRAS G12D 10mer肽，用于癌症免疫疗法研究的新抗原。

GADGVGKSA, 作为KRAS G12D 9mer肽的变体，充当免疫原性新抗原，在癌症免疫疗法研究中具有潜在应用价值。

GAGGVGKSA，作为wild-type KRAS G12D 9mer肽，具有免疫原性，可用于研究癌症免疫疗法中新抗原的应用。

Deltasonamide 1 TFA 是一种PDE6δ-KRas 抑制剂。Deltasonamide 1 可以抑制 PDE6δ-KRas，KD 为 203 pM。Deltasonamide 1 可用于肿瘤的研究。

SMAP-2 is an orally bioavailable activator of phosphatase 2A (PP2A) which binds to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. It inhibits the growth of KRAS-mutant lung cancers .